FOLH1 and neoplasm: Substitution of HBED-CC with DOTA and systematical modification of the side chain with the introduction of a naphtylic linker have led to PSMA-617 [8] with excellent pharmacokinetic properties, high binding affinity and internalization, prolonged tumor uptake, and high tumor-to-background ratio, which are extremely important for both imaging quality and therapy.